NCT04629287View on ClinicalTrials.gov

Safety,Tolerability, and Pharmacokinetic of KPCXM18 for Injection

PHASE1UnknownINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

February 28, 2022

Conditions
Healthy
Interventions
DRUG

KPCXM18

KPCXM18,blind,freeze-dried powder,ascending doses，Intravenous route

DRUG

Placebo

Placebo,blind,freeze-dried powder,ascending doses，Intravenous route

Sponsors
All Listed Sponsors
lead

Kunming Pharmaceuticals, Inc.

INDUSTRY